Surgeons at Hollywood, Fla.-based Joe DiMaggio Children's Hospital recently treated a patient with an opening defect in the wall of their heart using the first nonmetallic-framed transcatheter occluder.
The transcatheter has been implanted as part of the Ascent atrial septal defects U.S. Investigational Device Exemption pivotal trial, which will evaluate the device's safety and efficacy, according to a May 4 press release.
"We are pleased to be part of this global study and provide an innovative treatment to our pediatric patients who are suffering from this condition here in South Florida," said Larry Latson, MD, medical director of the hospital's pediatric and congenital interventional cardiology program. "With studies of this kind and world-wide collaboration, we are able to give our patients access to the most innovative treatments that will transform the way we treat congenital heart disease in the future."